Schering-Plough Gets EU Approval for Hepatitis C Treatment

Drug maker Schering-Plough said Monday it received expanded European approval for a combination therapy of Pegintron and Rebetol to treat hepatitis C patients who are also infected with HIV.

The combination therapy was originally approved in Europe in March 2001 for the treatment of hepatitis C alone. Both drugs are made by Schering-Plough .

The latest approval was based on two clinical studies showing that hepatitis C patients, with HIV, who were given Pegintron and Rebetol had significantly lower amounts of the hepatitis C virus six months after treatment compared with those patients given conventional interferon alfa-2b and ribavirin.

The company said about 40 percent of the 2.5 million people living in Europe with HIV were also infected with chronic hepatitis C.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Debating the plan to prevent tax inversions, Doug Holtz-Eakin, American Action Forum, says the Treasurys plan is worse than doing nothing. Christian Weller, Center for American Progress, explains why he favors inversion regulation.

  • CNBC's Eamon Javers discusses the Treasury Department's new rules to discourage companies from moving their headquarters overseas to avoid taxes.

  • Are Treasurys seeing a safe haven bid? CNBC's Rick Santelli and Bob Pisani break down the current action in bonds and equities.